Apellis Pharmaceuticals, Inc. $APLS Shares Bought by Profund Advisors LLC

Profund Advisors LLC lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 78.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 61,832 shares of the company’s stock after purchasing an additional 27,120 shares during the period. Profund Advisors LLC’s holdings in Apellis Pharmaceuticals were worth $1,553,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in APLS. Jones Financial Companies Lllp boosted its stake in Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after purchasing an additional 1,373 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of Apellis Pharmaceuticals by 141.2% in the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after acquiring an additional 1,570 shares during the last quarter. Allworth Financial LP raised its position in shares of Apellis Pharmaceuticals by 64.1% during the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after purchasing an additional 857 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at $64,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Apellis Pharmaceuticals by 338.5% during the second quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock valued at $94,000 after purchasing an additional 4,191 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ:APLS opened at $41.03 on Thursday. The company has a current ratio of 3.63, a quick ratio of 3.16 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $5.25 billion, a PE ratio of 40.23 and a beta of -0.24. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $41.14. The firm has a fifty day moving average price of $34.03 and a 200 day moving average price of $26.42.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Thursday, May 7th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.44. Apellis Pharmaceuticals had a return on equity of 39.71% and a net margin of 12.06%.The company had revenue of $268.30 million for the quarter, compared to analyst estimates of $208.91 million. Analysts expect that Apellis Pharmaceuticals, Inc. will post -1.14 EPS for the current fiscal year.

Analyst Ratings Changes

APLS has been the topic of a number of analyst reports. Robert W. Baird cut Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Cantor Fitzgerald reiterated a “neutral” rating on shares of Apellis Pharmaceuticals in a report on Friday, May 15th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $41.00 price objective (up from $37.00) on shares of Apellis Pharmaceuticals in a research report on Wednesday, April 1st. Weiss Ratings raised Apellis Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Finally, William Blair lowered shares of Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Three analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Apellis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $35.72.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.